William Paul Duprex
Paul Duprex | |
|---|---|
| Born | William Paul Duprex 1968 (age 55–56) emerging diseases, infections |
| Institutions | University of Pittsburgh |
| Website | http://www.cvr.pitt.edu |
William Paul Duprex (pronounced SARS-CoV-2 virus that caused the COVID-19 pandemic. Duprex is a Fellow of the American Academy of Microbiology.
Early life and education
Duprex, who goes by his middle name, Paul, was born to a
molecular virology in 1995.[1]
As a boy at King's Park Primary, he first discovered a love of science while observing tadpoles transform into frogs. Later, at Lurgan College, he discovered microbiology, experimenting with his classmates' saliva to determine which toothpaste was the best at killing the bacteria that colonize the mouth.[1]
Career
Early career
Duprex stayed on at QUB as a postdoctoral research fellow from 1995 to 1999, studying how measles virus infects the brain,[2][3][4] and served as a lecturer in molecular virology and biochemistry from 1999 to 2010, during which time he studied measles,[5] mumps,[6] canine distemper,[7] and foot-and-mouth disease virus[8] in biocontainment at the Pirbright Institute.[9]
Emerging infectious diseases, zoonosis, and vaccine development
From 2006 to 2007, Duprex worked at
Grand Challenges in Global Health to continue his work with heat-stable measles vaccines.[12] In 2018, Duprex became director of the Center for Vaccine Research at the University of Pittsburgh,[9] where he continues to study the evolution of human and animal respiratory viruses such as measles, mumps and SARS-CoV-2, with the practical goals of developing new vaccines for emerging diseases as well as tools that predict viral spillover from animal reservoirs into humans.[9]
COVID-19 response
Since the start of the COVID-19 pandemic, Duprex has used his public profile on
variants of concern.[28] With collaborators at Carnegie Mellon University, he is working on improving vaccine delivery systems that can more safely and effectively reach remote parts of the developing world.[29]
Selected publications
- Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study (2021). Clin Infect Dis., 73(3): e815–e821.
- Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses (2021). Science Advances, 7 (22), eabh0319.
- Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 (2020). Science, 370 (6523), 1479–1484.
- Animal models for COVID-19 (2020). Nature, 586:509-515. PMID 32967005.
- Persistence of severe acute respiratory syndrome coronavirus 2 in aerosol suspensions (2020). Emerging infectious diseases, 26 (9), 2168.
- Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection (2017). Nature Vaccines, 2 (1), 1–11.
- Recent mumps outbreaks in vaccinated populations: no evidence of immune escape (2012). Journal of virology, 86 (1), 615-620 103 2012.
- Early target cells of measles virus after aerosol infection of non-human primates (2011). PLoS pathogens, 7 (1), e1001263.
- Ligand-induced conformational changes allosterically activate Toll-like receptor 9 (2007). Nature immunology, 8 (7), 772–779.
- Predominant Infection of CD150+ Lymphocytes and Dendritic Cells during Measles Virus Infection of Macaques (2007). PLoS pathogens, 3 (11), e178.
- Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling (2002). Journal of virology, 76 (17), 8729–8736.
- Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus (1999). Journal of virology, 73 (11), 9568–9575.
Awards and honors
- 2013 - Gardner Prize Lectureship, European Society for Clinical Virology[30]
- 2018 - Fellow of the American Academy of Microbiology[31][32]
- 2021 - Carnegie Science Awards (25th Year): Chairman's Award[33][34]
References
- ^ a b c "Paul leading the fight against killer viruses". www.northernirelandworld.com. 26 August 2014. Archived from the original on 20 December 2021. Retrieved 20 December 2021.
- PMID 10400789.
- PMID 10933705.
- PMID 10516065.
- PMID 16033977.)
{{cite journal}}: CS1 maint: numeric names: authors list (link - PMID 19386700.
- PMID 17898047.
- PMID 18753210.
- ^ a b c "Pitt Announces New Director of Center for Vaccine Research". UPMC Life Changing Medicine. Retrieved 20 December 2021.
- ^ "Full Professorships for Eight on Medical Campus BU Today". Boston University. 11 March 2016. Retrieved 20 December 2021.
- ^ "Paul Duprex, Ph.D. » Program in Inflammatory Disorders | Boston University". www.bumc.bu.edu. Retrieved 20 December 2021.
- PMID 21616113.
- ISSN 0190-8286. Retrieved 20 December 2021.
- ^ "The coronavirus variants experts are most concerned about". www.cbsnews.com. 14 March 2021. Retrieved 20 December 2021.
- ^ "How do vaccines get approved for mass distribution? Doctors explain". TODAY.com. Retrieved 20 December 2021.
- ISSN 0362-4331. Retrieved 20 December 2021.
- ISSN 0362-4331. Retrieved 20 December 2021.
- ISSN 0190-8286. Retrieved 20 December 2021.
- ^ "COVID-19 will likely be with us forever. Here's how we'll live with it". Science. 22 January 2021. Archived from the original on 17 February 2021. Retrieved 20 December 2021.
- ^ "How COVID-19's Vaccine Development Will Benefit Future Vaccines". Science Friday. Retrieved 20 December 2021.
- ^ "Researchers At Pitt Working To Safely And Quickly Develop COVID-19 Vaccine". 27 February 2020. Retrieved 20 December 2021.
- ^ "UPMC Developing Test for COVID-19". UPMC & Pitt Health Sciences News Blog. 9 March 2020. Retrieved 20 December 2021.
- ^ "CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine". CEPI. Retrieved 20 December 2021.
- ^ US 11103576, Duprex, William Paul, "Measles virus vaccine expressing SARS-COV-2 protein(s)", issued 2021-08-31, assigned to University of Pittsburgh
- ^ "Merck Completes Acquisition of Themis". Merck.com. Retrieved 20 December 2021.
- ^ "Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates". Merck.com. Retrieved 20 December 2021.
- PMID 33536258.
- ^ "Tracking SARS-CoV-2 variants". www.who.int. Retrieved 20 December 2021.
- ^ University, Carnegie Mellon (17 February 2021). "Improving a Vaccine Delivery System for COVID and Beyond - News - Carnegie Mellon University". www.cmu.edu. Retrieved 20 December 2021.
- ^ "The Gardner Lectureship – European Society for Clinical Virology" (in Spanish). Retrieved 20 December 2021.
- ^ "American Academy of Microbiology". ASM.org. Retrieved 20 December 2021.
- ^ "ECOGIG - News Item". ecogig.org. Retrieved 21 December 2021.
- ^ "2019 Carnegie Science Award Winners". Carnegie Science Center. Retrieved 20 December 2021.
- ^ 2021 Carnegie Science Awards: Chairman's Award, retrieved 20 December 2021
External links
- William Paul Duprex on Twitter
- University of Pittsburgh Center for Vaccine Research
- "Chasing COVID" short documentary about Duprex's team on YouTube
| Authority control databases: Academics |
|---|
